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Assessment of epidemic projections using recent HIV survey 
data in South Africa: a validation analysis of ten 
mathematical models of HIV epidemiology in the 
antiretroviral therapy era
Jeﬀ rey W Eaton, Nicolas Bacaër*, Anna Bershteyn*, Valentina Cambiano*, Anne Cori*, Rob E Dorrington*, Christophe Fraser*, 
Chaitra Gopalappa*, Jan A C Hontelez*, Leigh F Johnson*, Daniel J Klein*, Andrew N Phillips*, Carel Pretorius*, John Stover*, Thomas M Rehle, 
Timothy B Hallett
Summary
Background Mathematical models are widely used to simulate the eﬀ ects of interventions to control HIV and to 
project future epidemiological trends and resource needs. We aimed to validate past model projections against data 
from a large household survey done in South Africa in 2012. 
Methods We compared ten model projections of HIV prevalence, HIV incidence, and antiretroviral therapy (ART) 
coverage for South Africa with estimates from national household survey data from 2012. Model projections for 2012 
were made before the publication of the 2012 household survey. We compared adult (age 15–49 years) HIV prevalence 
in 2012, the change in prevalence between 2008 and 2012, and prevalence, incidence, and ART coverage by sex and by 
age groups between model projections and the 2012 household survey. 
Findings All models projected lower prevalence estimates for 2012 than the survey estimate (18·8%), with eight 
models’ central projections being below the survey 95% CI (17·5–20·3). Eight models projected that HIV prevalence 
would remain unchanged (n=5) or decline (n=3) between 2008 and 2012, whereas prevalence estimates from the 
household surveys increased from 16·9% in 2008 to 18·8% in 2012 (diﬀ erence 1·9, 95% CI –0·1 to 3·9). Model 
projections accurately predicted the 1·6 percentage point prevalence decline (95% CI –0·3 to 3·5) in young adults 
aged 15–24 years, and the 2·2 percentage point (0·5 to 3·9) increase in those aged 50 years and older. Models 
accurately represented the number of adults on ART in 2012; six of ten models were within the survey 95% CI of 
1·54–2·12 million. However, the diﬀ erential ART coverage between women and men was not fully captured; all 
model projections of the sex ratio of women to men on ART were lower than the survey estimate of 2·22 (95% CI 
1·73–2·71).
Interpretation Projections for overall declines in HIV epidemics during the ART era might have been optimistic. 
Future treatment and HIV prevention needs might be greater than previously forecasted. Additional data about 
service provision for HIV care could help inform more accurate projections.
Funding Bill & Melinda Gates Foundation.
Copyright © Eaton et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Mathematical models are widely used to generate 
estimates and short-term projections of HIV epidemics1,2 
and to assess the costs and eﬀ ects of potential 
interventions to control the epidemic.3,4 These models 
synthesise epidemiological information, surveillance 
data, infectious disease theory, and assumptions about 
future conditions and intervention eﬀ orts to generate 
HIV epidemic projections. Model projections have 
become increasingly central to policy decision making 
and resource planning and allocation.5 For many uses, 
the value of these analyses for public health decision 
making depends on the accuracy of their projections.
The most important recent change in HIV 
epidemiology has been the provision of antiretroviral 
therapy (ART) in low-income and middle-income 
countries, with the number receiving ART in low-income 
and middle-income countries increasing from 300 000 in 
2002 to an estimated 9·7 million at the end of 2012.6 
Successful ART both improves survival for HIV-positive 
people, potentially up to near-normal life expectancy,7 
and inhibits onward transmission of the virus.8 This 
preventive eﬀ ect has raised myriad questions about the 
future trajectory of HIV epidemics, whether existing 
ART programmes are suﬃ  cient to reduce incidence, 
whether countervailing factors will limit any eﬀ ect, and 
what resources are needed for future ART provision in 
the short and long term.9
In response to these questions, many models have 
been used to quantify the short-term and long-term 
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consequences of current and future ART provision on 
HIV prevalence, incidence, and mortality,4,10,11 including 
assessment of the potential use of ART to substantially 
reduce or eliminate HIV transmission.12–14 A comparison 
of models for South Africa showed that although the 
long-term eﬀ ect of ART on incidence varied substantially, 
models’ short-term projections of basic metrics were 
similar.10 This agreement increased conﬁ dence in these 
projections, but assessment of the accuracy of those 
projections, and by implication the conﬁ dence that 
should be placed on the longer-term projections of these 
models, was not possible.
Data are now available from a large household survey 
done in 2012,15 which has provided nationally 
representative measurements of HIV prevalence, 
incidence, and ART coverage in South Africa to which 
earlier model projections can be compared. During the 
period between the national surveys in 2008 and 2012, 
the number of people receiving ART in South Africa 
increased by three times—from 730 000 to 
2·2 million16—a surge expected to bring large reductions 
in HIV incidence.10 We used the 2012 household survey 
data15 to undertake a validation of the previously 
published short-term model projections of the South 
African HIV epidemic in 2012.
Methods
Study design
We compared existing projections of HIV prevalence, 
HIV incidence, and ART coverage by age and sex from 
ten mathematical models of the national HIV epidemic 
in South Africa with empirical estimates from the South 
African National HIV Prevalence, Incidence and 
Behaviour Survey, 2012 (henceforth referred to as the 
2012 household survey).15
Mathematical models
Ten mathematical models produced projections for adult 
HIV prevalence, HIV incidence, and ART coverage for 
the period 2002–12 (table). All models stratiﬁ ed the 
population by sex, producing projections for men and 
women. Eight of the models were age structured and 
reported results by 5-year age groups.
All of the models generated internally consistent 
patterns of HIV prevalence, incidence, and mortality 
through a non-linear dynamic transmission process in 
which the number of new infections was a function of 
the number infected and the population at risk. All 
models except the Estimation and Projection Package 
(EPP) generated new infections as a function of sexual 
contacts and transmission probabilities per contact over 
the course of the epidemic. In EPP, the rate at which 
infected individuals generated new infections was 
estimated as a ﬂ exible smooth function over time.28 For 
the age-structured models, the rate of forming new 
sexual partnerships and sexual mixing (ie, the patterns 
of how sexual partnerships are formed) depended on the 
ages of each partner (for EPP and Goals, the HIV 
incidence rate ratio is a function of age). All models 
except pre-PopART assumed reductions in the risk of 
condomless sexual contacts or transmission over the 
course of the epidemic, mediated by increases in 
condom use (ASSA, Bacaër, EMOD, Goals, STDSIM, 
STI-HIV, and Synthesis), reductions in sexual contact 
(Eaton, EPP, and Goals), or improvements in the control 
of sexually transmitted infections (ASSA and Goals). 
Increases in condom use were greater among young 
adults than among older adults (ASSA, Bacaër, EMOD, 
STDSIM, and STI-HIV), resulting in greater relative 
reductions in the risk of condomless sexual contact over 
the course of the epidemic for younger adults. All 
models assumed reduced mortality for adults on ART 
and assumed that transmission by people on ART was 
reduced by at least 90%.
Models diﬀ ered in the data used to calibrate epidemic 
trends, the approach to calibration, and which 
parameters were allowed to vary (table). Four models 
(EMOD, Goals, pre-PopART, and STDSIM) relied on 
UNAIDS prevalence estimates to calibrate the overall 
prevalence trend, whereas the others calibrated directly 
Research in context
Evidence before this study
Many mathematical models have been developed to project the 
epidemiological and demographic eﬀ ects of antiretroviral 
therapy (ART) on HIV epidemics and assess diﬀ erent policy 
options for the use of ART across sub-Saharan Africa and 
elsewhere. However, testing of these predictions against external 
data had not been possible. With new data from a nationally 
representative household survey in South Africa, we have, for the 
ﬁ rst time, compared existing model projections with data about 
HIV prevalence, HIV incidence, and ART coverage.
Added value of this study
Models were consistent with new data in projecting prevalence 
declines among younger adults and a shift in the age 
distribution of HIV. However, model projections did not predict 
the overall increase in adult HIV prevalence since the scale-up of 
ART and underestimated current incidence levels.
Implications of all the available evidence
Our results suggest that existing projections for reductions in 
HIV incidence after the scale-up of ART might have been 
overly optimistic. Resources needed for future HIV treatment 
and prevention are probably greater than previously 
forecasted. Incorporating more detailed data about patterns 
of uptake of health services could improve future 
epidemiological and demographic projections for HIV and 
other diseases.
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to prevalence estimates from antenatal clinic 
surveillance since 1990 and national household surveys 
in 2002, 2005, and 2008. ASSA, Bacaër, and STI-HIV 
were calibrated to age-speciﬁ c and sex-speciﬁ c HIV 
prevalence from household and antenatal clinic surveys. 
Synthesis was calibrated only to national survey 
prevalence among adults aged 15–24 years and 
15–49 years by sex, and did not incorporate antenatal 
clinic prevalence. One model, ASSA, included the time 
series of corrected national all-cause mortality estimates 
in the model calibration. Eight models used an 
optimisation routine to identify parameters that 
produced epidemics closest to the calibration data 
(table). Three models (Eaton, EPP, and STI-HIV) were 
statistically calibrated using a Bayesian approach to 
estimate posterior distributions for both uncertain 
model parameters and outcomes of interest. These 
models reported 95% credible ranges for model 
outcomes in the analyses.
All model projections analysed were produced between 
2010 and 2012 (table), before the analysis and publication 
of the 2012 household survey results. NB updated the 
Bacaër model projection to incorporate numbers of 
adults on ART from 2010 to 2012, but no changes were 
made to any other aspects of model structure or 
assumptions.
2012 survey data
The 2012 household survey was a stratiﬁ ed nationally 
representative household survey done between January, 
2012, and November, 2012.15 It was the fourth such survey 
in South Africa, following similar surveys in 2002, 2005, 
and 2008.29–31 Full details of the survey design and results 
are described elsewhere.15 Brieﬂ y, a nationally 
representative sample of 30 747 adults aged at least 
15 years was randomly sampled using a two-stage cluster 
design, of whom 20 693 participated in an individual 
interview and provided a dried blood spot for HIV 
Model 
name 
Type Age 
structured
MTCT 
survival*
Time projection 
created and source
Main calibration data Calibration approach
Dorrington et al (2010)2 ASSA Compartmental Yes Yes March, 201117 Provincial age-speciﬁ c and sex-speciﬁ c 
HSRC prevalence in 2002, 2005, and 
2008; ANC prevalence 1991–2008; and 
age-speciﬁ c and sex-speciﬁ c total deaths 
1997–2008
Hand-tuned calibration
Bacaër et al (2010)18 Bacaër Compartmental Yes Yes March, 201010† Age-speciﬁ c and sex-speciﬁ c HSRC 
prevalence in 2002, 2005, and 2008; 
and age-speciﬁ c ANC prevalence 
1990–2008
Hand-tuned calibration
Eaton and Hallett 
(2014)19
Eaton Compartmental No No November, 201110 Sex-speciﬁ c HSRC prevalence in adults 
aged 15–49 years in 2002, 2005, and 
2008; and ANC prevalence 1990–2010
Bayesian statistical calibration of sexual 
mixing and behaviour change parameters
Klein et al (2014)20 EMOD‡ Individual-based Yes Yes December, 20124 UNAIDS 2012 estimates for prevalence 
in adults aged 15–49 years; and HSRC for 
age pattern in 2005 and 2008
Hand-tuned calibration with varying 
transmission probability, condom use, and 
concurrency
Stover et al (2012)21 EPP§ Compartmental Yes§ Yes November, 201222 HIV prevalence trend derived from 
provincial ANCs, HSRC prevalence in 
adults aged 15–49 years in 2002, 2005, 
and 2008
Bayesian statistical calibration of force of 
infection
Avenir Health (2015)23 Goals§ Compartmental Yes§ Yes December, 20124 UNAIDS 2011 prevalence estimates Hand-tuned calibration of model 
parameters
Cori et al (2014)24 pre-PopART Compartmental No No December, 201224 UNAIDS 2008 prevalence estimates Least-squares optimisation for sexual 
mixing parameters
Hontelez et al (2013)13 STDSIM Individual-based Yes No December, 20124 UNAIDS 2012 prevalence estimates Random sampling from ranges for 
number of new partners and condom use 
parameters
Johnson et al (2012)25 STI-HIV Compartmental Yes Yes November, 201110 Age-speciﬁ c and sex-speciﬁ c HSRC 
prevalence in 2005 and 2008; and age-
speciﬁ c ANC prevalence 1997–2005
Bayesian statistical calibration of sexual 
mixing, transmission, and condom use 
parameters
Phillips et al (2011)26 and 
Cambiano et al (2013)27
Synthesis Individual-based Yes No December, 20124 Sex-speciﬁ c HSRC prevalence in 
15–24-year-olds and 15–49-year-olds in 
2002, 2005, and 2008
Sampled from distributions for behaviour 
change and transmission probability 
parameters
References for each model provide further details regarding the assumptions about sexual behaviour, ART, and other aspects of model structure, parameters, implementation, and calibration. ANC=antenatal 
clinic. ART=antiretroviral therapy. EPP=Estimation and Projection Package. HSRC=Human Sciences Research Council. MTCT=mother-to-child transmission. *Whether or not models incorporated MTCT of HIV 
and potential survival of these infections to adolescence. †Updated in August, 2013, to simulate current numbers on ART from 2010 to 2012. ‡Version 0.8. §EPP and Goals are separate models that each produce 
non-age-structured HIV incidence for the 15–49 years age group. Both models are then fed into the AIDS Impact Module of the Spectrum package, which applies demographic structure and a ﬁ xed age pattern of 
HIV incidence.
Table: Mathematical models included 
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testing. Dried blood spots were tested for HIV antibodies 
using a three-assay testing algorithm. HIV-positive 
specimens were tested for the presence of antiretrovirals 
using high-performance liquid chromatography coupled 
with tandem mass spectrometry. HIV incidence was 
estimated using a testing algorithm based on the 
limiting-antigen avidity assay for recent infection,32 
antiretroviral testing, and viral load testing.15 Results of 
the survey were published in April, 2014. Empirical adult 
mortality rates for 2003 to 2012 were drawn from 
estimates derived from the rapid mortality surveillance 
system.33
Statistical analysis
The main outcomes compared between model 
projections and the 2012 household survey were adult 
(age 15–49 years) HIV prevalence in 2012 and the 
change in adult (age 15–49 years) prevalence between 
2008 and 2012. Changes in prevalence refer to absolute 
percentage point changes, not relative changes. We also 
compared prevalence, incidence, and ART coverage 
(deﬁ ned as the percentage of HIV-positive adults on 
ART) by sex and by age groups (15–24, 25–49, and 
≥50 years) for the eight models that produced age-
structured estimates. We compared the change in 
simulated prevalence from 2005 to 2008 with the 
projected change in prevalence from 2008 to 2012 to 
assess the eﬀ ect of model calibration on future model 
projections. We compared modelled trends in adult 
(15–49 years) mortality with national estimates from the 
rapid mortality surveillance system.33
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, writing 
of the report, or the decision to submit for publication. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
Five models projected that prevalence in adults aged 
15–49 years in 2012 would change by 0·3 percentage 
points or less from prevalence in 2008. Three models 
projected prevalence declines of 0·7 to 1·3 percentage 
points. (ﬁ gure 1). One model, STI-HIV, projected an 
increase in prevalence of 0·9 percentage points (95% CI 
0·6–1·4; ﬁ gure 1C).
However, the household surveys estimated that adult 
prevalence increased from 16·9% in 2008 to 18·8% in 
2012 (diﬀ erence 1·9, 95% CI –0·1 to 3·9; ﬁ gure 1C). As a 
result, all models projected lower prevalence estimates 
for 2012 than the survey estimate (18·8%), with eight of 
ten models’ central projections being below the survey 
95% CI (17·5–20·3; ﬁ gure 1B).
The disparity between the 2012 survey estimate and the 
ten model estimates was driven by eight models 
projecting that prevalence would decline among men, 
whereas 2012 household survey data estimated that 
prevalence increased by 2·9 percentage points (95% CI 
0·3–5·5; ﬁ gure 2A). Only STI-HIV (mean 0·5 percentage 
point increase) was within the survey 95% CI (ﬁ gure 2A). 
Among women, seven models projected that prevalence 
Figure 1: Projections for HIV prevalence in adults aged 15–49 years
(A) Projected trend for prevalence in adults aged 15–49 years from 2002 to 2012. Circles show national survey estimates in 2002, 2005, 2008, and 2012, with 
95% CIs (bars). (B) Model projections for prevalence in adults aged 15–49 years in 2012 and (C) absolute (percentage point) change in HIV prevalence in adults 
aged 15–49 years from 2008 to 2012. Dashed horizontal lines show household survey estimates and grey regions show 95% CIs around these estimates. 
Shaded areas around model projections show 95% Bayesian credible regions for the three models that estimated statistical uncertainty around model estimates 
and projections. EPP=Estimation and Projection Package.
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would increase, with ASSA, STI-HIV, and Synthesis 
projecting increases of larger than 0·9 percentage points 
(ﬁ gure 2A). The survey data conﬁ rmed this trend, with 
an estimated increase of 1·9 percentage points (95% CI 
–0·8 to 4·6).
Despite this disparity, prevalence estimates in 2012 
tended to be more accurate for men, whereas for 
women all models’ central projections except STI-HIV 
were below the survey 95% CI (ﬁ gure 2B). This ﬁ nding 
was because models tended to simulate prevalence in 
2008 as being higher among men and lower among 
women than suggested by the 2008 household survey 
(appendix). 
All eight age-structured models projected that 
prevalence would decline for men and women aged 
15–24 years and increase for men and women aged 
50 years and older (ﬁ gure 3), consistent with an overall 
ageing of the epidemic proﬁ le. This prediction was 
conﬁ rmed by the 2012 household survey data, which 
showed declines between 2008 and 2012 of 
0·9 percentage points (95% CI –1·2 to 3·0) for young 
men and 2·1 percentage points (–0·6 to 4·8) for young 
women, and increases in prevalence among men and 
women aged 50 years and older of 2·0 percentage points 
(–0·9 to 4·8) and 2·4 percentage points (0·4 to 4·3), 
respectively (ﬁ gure 3).
For women aged 25–49 years, all models projected 
that prevalence would increase by between 
1·1 percentage points and 2·7 percentage points. The 
survey point estimate suggested a greater increase of 
4·1 percentage points (95% CI 0·3–7·8). The largest 
discrepancy between model projections and survey 
point estimates was among men aged 25–49 years. Six 
models projected declining prevalence and EPP and 
STI-HIV projected slight increases, whereas point 
estimates from the household surveys suggested that 
prevalence increased by 2·0 percentage points (95% CI 
–2·1 to 6·2).
Most model projections closely matched the age 
distribution of the South African population in 2012 
(appendix). The proportion of adults aged 30–50 years 
was under-represented in some models (Bacaër, EMOD, 
STDSIM, and Synthesis), which contributed to the 
underestimation of the overall prevalence increases 
among adults aged 15–49 years.
Models were similar in their representation of a rapid 
scale-up of ART in South Africa (ﬁ gure 4A). The 
household survey estimated 1·83 million (95% CI 
1·54–2·12 million) adults aged at least 15 years were on 
ART in 2012; six of ten models were within this survey 
95% CI. However, all model projections of the sex ratio of 
women to men on ART were lower than the survey 
estimate of 2·22 (95% CI 1·73–2·71; ﬁ gure 4B). Models 
were largely accurate in their projections for the age 
distribution of adults on ART, although three models—
Bacaër, EPP, and STDSIM—overestimated the 
proportion of treated adults who were aged 25–34 years 
(ﬁ gure 4C). ART coverage was particularly overestimated 
among men aged 25–49 years (appendix).
Models simulated declines in HIV incidence in adults 
aged 15–49 years of between 40% and 54% over the 
decade 2002–12 (calculated using the following formula: 
1 – [2012 incidence rate]/[2002 incidence rate]; 
appendix). Projections for HIV incidence in 2012 
ranged from 1·0 per 100 person-years to 1·4 per 
100 person-years. These estimates were lower than the 
survey estimate of 1·7 per 100 person-years (95% CI 
1·4–2·1), which was based on the recent infection assay. 
For men, the projections were consistent with the 
estimate of HIV incidence in the 2012 household 
Figure 2: HIV prevalence by sex among adults aged 15–49 years
(A) Projected absolute (percentage point) change in prevalence between 2008 
and 2012 for men (horizontal axis) and women (vertical axis). (B) HIV 
prevalence in 2012. Dashed lines show 2012 household survey estimates and 
grey shaded strips show survey 95% CIs. Shaded areas around model 
projections show 95% credible intervals for the two models that estimated 
statistical uncertainty around model estimates and projections for this 
outcome. EPP=Estimation and Projection Package.
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survey, but for women all model estimates of HIV 
incidence were substantially lower than the 2012 
household survey estimate (ﬁ gure 5).
Empirical estimates suggest that adult (15–49 years) 
mortality rates among both men and women peaked in 
2005 and declined by 36% among men and by 45% 
among women by 2012.33,34 Excluding one model—
Bacaër—model projections simulated adult mortality 
peaking in 2005 or 2006 and declining by 22–37% for 
men and 25–45% for women (calculated as the percentage 
reduction in mortality rate from 2005 to 2012: 
(1 – [2012 mx])/ [2005 mx]; ﬁ gure 6A). All model 
projections of crude mortality rates in 2012 were higher 
than estimates from the rapid mortality surveillance 
system33 estimates (ﬁ gure 6B).
In general, models calibrated to age-speciﬁ c 
prevalence from earlier national survey data (ASSA, 
Bacaër, STI-HIV, and Synthesis) more closely matched 
reported prevalence changes between 2005 and 2008 
than did models calibrated to antenatal clinic 
prevalence or UNAIDS prevalence estimates 
(appendix). Furthermore, these models tended to 
project larger increases in prevalence between 2008 
and 2012 (appendix). Conversely, models that did not 
use age-structured data (Eaton and EPP) or were 
calibrated to UNAIDS prevalence (EMOD, Goals, pre-
PopART, and STDSIM) did not capture either the 
earlier (2005–08) or later (2008–12) prevalence 
increases. The outlier to the positive association 
between prevalence change from 2005 to 2008 and the 
projected change from 2008 to 2012 was Bacaër, which 
compared the model ﬁ t to age-speciﬁ c prevalence data 
during tuning of model parameters, but not in a 
systematic way.
Discussion
Demand for evidence-based policies and eﬃ  cient 
allocation of resources for health have made 
mathematical modelling an integral component of 
public health decision making, with many models often 
being applied to the same question. We assessed the 
accuracy of short-term model projections from HIV 
transmission models in South Africa over the period of 
rapid ART scale-up. Mathematical models consistently 
predicted important epidemiological changes that were 
conﬁ rmed by new survey data—in particular the 
reduction in prevalence among young adults and 
increased prevalence among older adults. Models 
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Figure 3: Change in HIV prevalence between 2008 and 2012 by sex and 
age group
Dashed lines show estimates from successive household surveys with grey 
shaded regions showing survey 95% CIs. Eaton and pre-PopART models are not 
included because these models were not age structured. Circles show the 
estimate for the prevalence change for the model; coloured lines show the 
change from 0. Shaded areas around STI-HIV model estimates show 95% 
credible intervals (no other models estimated statistical uncertainty around 
model estimates for this outcome). EPP=Estimation and Projection Package.
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accurately projected the number and age distribution of 
those on ART, captured the peak in adult mortality 
around 2005 and declines thereafter, and were consistent 
or conservative about the magnitude of reductions in 
adult mortality. However, there were also important 
features of the 2012 household survey data that were not 
anticipated by the model projections, most importantly 
the magnitude of increase in adult HIV prevalence, 
particularly among 25–49-year-old men, and the 
substantially larger number of women than men on 
ART. These ﬁ ndings have implications for under-
standing the course of the epidemic in South Africa, 
and by extension other settings with large epidemics, 
and provide insights on issues that future projections 
should incorporate, in HIV and other areas of public 
health planning. 
Some apparent discrepancies between the survey data 
and model projections could be the result of random 
sampling variation, biases in the survey data, or changes 
in the survey sampling procedures. 95% CIs around 
survey estimates were wide for prevalence changes 
between surveys and for some subpopulations. Among 
women, it seems likely that prevalence truly did increase 
more than was predicted by models because of the 
consistency of this across diﬀ erent outcomes—model 
projections were lower than survey estimates for both 
prevalence and incidence, and some underestimated 
mortality reductions. Models also overestimated ART 
coverage in middle-aged men and the successive surveys 
suggested decreases in condom use (whereas models 
assumed no changes in sexual risk behaviour),15 both of 
which would result in models underestimating 
incidence among women. Furthermore, changes in 
Figure 4: Antiretroviral therapy coverage in 2012
(A) Model projections for the number of adults aged 15 years and older on ART over 
time. The datapoint shows the mean 2012 household survey estimate and the error 
bar shows the 95% CI. (B) Sex ratio of number of adult (aged ≥15 years) women to 
men on ART in 2012. The dashed line shows the 2012 household survey estimate, 
with the 95% CI shown as a grey shaded region. For EPP and Goals, the numbers of 
men and women on ART is an input for the Spectrum model. Shaded areas around 
model projections show 95% credible intervals for the two models that estimated 
statistical uncertainty around model estimates for this outcome. (C) Age distribution 
of adults on ART in 2012 by age groups 15–24 years, 25–34 years, 35–49 years, and 
≥50 years. Solid lines show 2012 household survey estimates and dashed horizontal 
lines show 95% CIs. ART=antiretroviral therapy. EPP=Estimation and Projection Package. 
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Figure 5: HIV incidence rates in adults aged 15–49 years in 2012
Rates are shown for men (left) and women (right). Horizontal dashed lines show estimates from the 2012 
household survey and grey shaded regions show the survey 95% CIs. Shaded areas around model projections 
show 95% credible intervals for the two models that estimated statistical uncertainty around model estimates for 
this outcome. EPP=Estimation and Projection Package.
0
0·5
1·0
1·5
2·0
2·5
3·0
H
IV
 in
cid
en
ce
 (p
er
 1
00
 p
er
so
n-
ye
ar
s)
Men Women
AS
SA
Ba
caë
r
Ea
ton
EM
OD EP
P
Go
als
Pre
-Po
pA
RT
ST
DS
IM
ST
I-H
IV
Sy
nth
esi
s
AS
SA
Ba
caë
r
Ea
ton
EM
OD EP
P
Go
als
Pre
-Po
pA
RT
ST
DS
IM
ST
I-H
IV
Sy
nth
esi
s
Articles
e605 www.thelancet.com/lancetgh   Vol 3   October 2015
age-speciﬁ c prevalence estimated by the survey are 
consistent with age-speciﬁ c trends from national 
antenatal clinic surveillance.35
However, among men, the magnitude of prevalence 
increases suggested by consecutive surveys seems harder 
to reconcile. Models did not systematically underestimate 
incidence in men, and models overestimated ART 
coverage for men, which should have led model estimates 
of prevalence among men to be too high and mortality 
too low—the opposite of what we found. One possible 
explanation is that the 2008 household survey 
underestimated prevalence in men because of random 
sampling error or bias, which would have aﬀ ected the 
model projections.
Models that relied directly on age-speciﬁ c household 
survey data were associated with a better representation 
of earlier trends in prevalence and more accurate 
projections of the trends in 2008–12 than those that 
used UNAIDS prevalence estimates. In particular, the 
STI-HIV model projection was closest to the prevalence 
levels and changes in the 2012 household survey. This 
model applied a formal statistical approach to calibration 
of model parameters to age-speciﬁ c HIV prevalence 
data from two previous household surveys and 
age-speciﬁ c antenatal clinic prevalence. Age-aggregated 
antenatal clinic prevalence or UNAIDS prevalence 
estimates, as a calibration source, are likely to have 
misrepresented recent epidemic prevalence trends from 
2005 to 2008, and 2008 to 2012, because of downward 
biases in antenatal clinic prevalence as HIV prevalence 
shifts to older, less fertile age groups.36 For South Africa, 
mortality data are another potential source for 
calibration models that have not been widely used, 
although the scope for this is probably limited in other 
generalised HIV epidemic settings without vital 
registration.
Even the models that were calibrated from previous 
household surveys did not match the increase in HIV 
prevalence in adults aged 15–49 years suggested by the 
2012 household survey. There are several potential 
explanations for this. Models might not have captured 
the extent to which early ART uptake was dominated by 
initiation of ART in the sickest patients at high risk of 
dying; instead, most models considered all people with 
CD4 cell counts less than 200 cells per μL to have the 
same risk of mortality and HIV transmission and 
likelihood of starting ART. This assumption could result 
in models underestimating reductions in mortality and 
overestimating the infections averted because the sickest 
patients are unlikely to be transmitting HIV. Both factors 
would contribute to an underestimation of HIV 
prevalence.
Models might also have overestimated the eﬀ ectiveness 
of ART at averting HIV transmission at the population 
level, or might have underestimated the eﬀ ectiveness of 
ART at reducing HIV deaths. Model assumptions about 
the individual eﬃ  cacy of ART at reducing mortality and 
transmission are based on randomised trial data37–39 and 
supported by observational data,40–42 which have been 
used to develop model assumptions. However, models 
might not have incorporated the persistent challenges in 
adherence and retention on ART that could limit the real-
world eﬀ ectiveness of ART at averting transmission 
compared with that achieved in trials. For example, 
models overestimated ART coverage among men aged 
25–49 years, probably because they did not account for 
lower levels of HIV testing, treatment uptake, and 
retention on ART that have been consistently shown 
among men.43
Ongoing community-based trials of HIV treatment as 
prevention will generate evidence about the eﬀ ects of 
large expansions of ART on population-wide HIV 
incidence (NCT01965470).44,45 The ramiﬁ cations of our 
ﬁ ndings for these trials depends on the underlying 
explanation for why prevalence and incidence were 
underestimated. If existing ART uptake has been more 
concentrated among the sickest patients and not those 
responsible for onward HIV transmission, then test-and-
treat intervention strategies might have an even larger 
eﬀ ect than existing projections if they can eﬀ ectively 
Figure 6: Model projections of mortality rate in adults aged 15–49 years
Projected trend for (A,B) the period 2002–12 and (C,D) in the year 2012. The crosses in (A,B) and dashed lines in 
(C,D) show empirical adult mortality estimates from the rapid mortality surveillance system, 2012.33 Eaton and 
pre-PopART models are not included because these models do not produce total mortality estimates. 
EPP=Estimation and Projection Package. 
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enrol people who are not accessing current treatment 
programmes. However, if the higher than anticipated 
incidence is the result of models having overestimated 
the real-world eﬀ ectiveness of ART at preventing 
transmission, ART might reduce incidence less than 
expected based on model predictions.
Behavioural data from the 2012 household survey 
suggested increases in the proportion of adults who have 
several sexual partnerships and decreases in consistent 
condom use since 2008, whereas the models included in 
this comparison assumed that sexual behaviour would 
remain the same in the future. This diﬀ erence represents 
one potential explanation for the underestimation of 
incidence by the models. However, increases in reported 
risk from the survey were largest among young adults 
aged 15–24 years, whereas model projections 
underestimated prevalence to a greater extent among 
older adults. Also, other recent survey data from South 
Africa have shown continuing reductions in risk 
behaviour.46,47 Nevertheless, this survey ﬁ nding 
emphasises the need to consider uncertainty about 
future changes in sexual behaviour in projections about 
the future course of the epidemic.
Compared with earlier eras in the HIV epidemic or 
other disease epidemics, all models were accurate, 
including capturing the overall magnitude of the 
epidemic, changes in the age pattern of the epidemic, 
and changes in mortality. This increased accuracy is 
largely attributable to the substantial investments in 
HIV surveillance and epidemiology from which these 
models have been developed and improved. However, 
aspects of our results also provide caution that 
consistency of a prediction by many models does not 
necessarily imply the correctness of the prediction, 
especially when models rely on the same information 
and the same understanding and interpretations of data 
and events. For example, several models calibrated to the 
same model-based epidemic estimates published by 
UNAIDS, and no model captured the magnitude of the 
sex diﬀ erentials in uptake of ART. Epidemic estimates 
and short-term projections using models could be 
improved by (1) direct calibration to epidemiological 
data and careful interpretation of data from 
subpopulations such as pregnant women attending 
antenatal clinics; (2) carefully considering model 
assumptions underlying the eﬀ ectiveness of ART at 
reducing transmission; and (3) incorporating infor-
mation about the clinical, demographic, and epi-
demiological characteristics of those accessing services. 
Thus rapid, open, and routine reporting of clinical and 
programmatic data such as numbers tested, linked to 
care, initiated on ART, and defaulting, stratiﬁ ed by age 
and sex, are essential to improve model estimates and 
projections.
Although our analysis focused on the data-rich 
setting of South Africa, the lessons for HIV 
epidemiology and prevention generated are relevant 
more widely in generalised HIV epidemic settings in 
sub-Saharan Africa. Our ﬁ ndings do not necessarily 
contradict the theory that treatment could have, or has 
already had, a large eﬀ ect on reducing transmission. 
They do suggest that expectations might have been 
overly optimistic about the extent to which HIV 
transmission would reduce as ART was scaled up, 
particularly for mid-aged (age 25–49 years) adults 
among whom prevalence and incidence were most 
consistently higher than anticipated. A further 
implication is that achieving targets for reductions in 
HIV incidence might require more intervention 
resources and longer time periods than previously 
forecasted. When HIV prevalence was assumed to be 
steadily increasing over the past decade, achievement 
of incidence reduction targets was estimated to take 
nearly three times as long as when prevalence was 
assumed to be constant.13 As models are increasingly 
used to support policy planning, advocate and allocate 
resources, and assess programmes, surveillance and 
trial data must also continue to be collected to validate 
and improve the information that underlie these 
processes.
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